- Open Access
Clinical characteristics and antibiotic resistance profile of invasive MRSA infections in newborn inpatients: a retrospective multicenter study from China
BMC Pediatrics volume 23, Article number: 264 (2023)
Methicillin-resistant Staphylococcus aureus (MRSA) can cause invasive infections with significant mortality in neonates. This study aimed to analyze the clinical characteristics and antibiotic resistance profiles of invasive MRSA infections and determine risk factors associated with invasive MRSA infections in newborn inpatients.
This multicenter retrospective study of inpatients from eleven hospitals in the Infectious Diseases Surveillance of Pediatrics (ISPED) group of China was performed over a two-year period (2018–2019). Statistical significance was calculated by applying the χ2 test or by Fisher’s exact test in the case of small sample sizes.
A total 220 patients were included. Among included cases, 67 (30.45%) were invasive MRSA infections, including two deaths (2.99%), while 153 (69.55%) were noninvasive infections. The invasive infections of MRSA occurred at a median age of 8 days on admission, which was significantly younger compared to 19 days in noninvasive cases. Sepsis (86.6%) was the most common invasive infection, followed by pneumonia (7.4%), bone and joint infections (3.0%), central nervous system infection (1.5%), and peritonitis (1.5%). Congenital heart disease, low birth weight infant (<2500 g), but not preterm neonates, and bronchopulmonary dysplasia, were more commonly found in invasive MRSA infections. All these isolates were susceptible to vancomycin and linezolid and were resistant to penicillin. Additionally, 69.37% were resistant to erythromycin, 57.66% to clindamycin, 7.04% to levofloxacin, 4.62% to sulfamethoxazole-trimethoprim, 4.29% to minocycline, 1.33% to gentamicin, and 3.13% were intermediate to rifampin.
Low age at admission (≤8 days), congenital heart disease, and low birth weight were associated with invasive MRSA infections in neonates, and no isolates resistant to vancomycin and linezolid were found. Determining these risks in suspected neonates may help identify patients with imminent invasive infections who may require intensive monitoring and therapy.
Methicillin-resistant Staphylococcus aureus (MRSA), which was first reported in the United States in 1961 and first described in the neonatal ward in 1981 , is a formidable pathogen that is commonly found in neonatal intensive care units (NICUs). The prevalence of neonatal MRSA colonization was reported in 3.9-8.4% of neonates, among whom one-forth developed MRSA infections [2,3,4], and 33-67% of S.aureus infections in neonates were caused by MRSA [5, 6]. MRSA outbreaks remain an ongoing concern in neonatal care and are increasingly complicated by high rates of resistance. MRSA can cause serious infections in the newborn, and has caused mortality in many countries throughout the world [7, 8]. While it is well known that neonates are vulnerable to invasive infection with MRSA, there is a real shortage of neonatal data on the profiles of MRSA infection and antimicrobial resistance rates.
Herein, we analyzed the clinical and antibiotic resistance profiles of invasive MRSA infections in neonatal from eleven hospitals within the Infectious Diseases Surveillance of Pediatrics (ISPED) group of China over a two-year period (2018–2019) and factors related to severity.
Materials and methods
This study was conducted across eleven hospitals within the ISPED group of China between January 2018 and December 2019. There are a total of 314 newborns. According to the clinical manifestations and treatment response of the children, 94 cases that were considered to be colonized or contaminated by MRSA were excluded. A total of 220 MRSA infections were obtained. The total number of S. aureus infections was 659, and the proportions of MRSA infections were 33.38%. 220 cases of MRSA infection from the following hospitals: Children’s Hospital of Fudan University (67), Children’s Hospital of Zhejiang University School of Medicine (55), Children’s Hospital of Chongqing Medical University (18), Qilu Children’s Hospital of Shandong University (11), Shenzhen Children’s Hospital (10) Xi’an Children’s Hospital (10), Second Affiliated Hospital & Yuying Children’s Hospital of Wenzhou Medical University (10), Shanghai Children’s Medical Center of Shanghai Jiaotong University School of Medicine (10), Kaifeng Children’s Hospital (10), Bethune First Hospital of Jilin University (10) and Children’s Hospital of Shanghai Jiaotong University School of Medicine (9) were included in the analysis.
We reviewed the medical records of neonatal hospital inpatients with MRSA infections using a standardized data sheet, which included sex, age, underlying disease, infection site, clinical symptoms, treatments, prognosis, hospital stay length, and antibiotic resistance profile. All collected medical data were independently reviewed by two doctors. If multiple specimens from a single patient yielded MRSA-positive cultures, it was counted as a single case; however, strains from different specimen sources of the same patient were counted as different isolates. Species identification was performed by standard biochemical methods.
Case definitions and ascertainment
Invasive MRSA infections were defined as clinical infections with isolation of MRSA from normally sterile body sites, such as blood, cerebrospinal fluid, pericardial fluid, pleural fluid, peritoneal fluid, bone, and joint fluid or other internal body sites.
Sepsis was defined as systemic inflammatory response syndrome (SIRS) associated with infection . The SIRS in children was defined with the presence of at least two of the following four criteria, one of which needed to be abnormal temperature or leukocyte count: (1) cored temperature of >38.5℃ or <36℃; (2) tachycardia or bradycardia; (3) mean respiratory rate increased; (4) leukocyte count elevated or depressed for age or >10% immature neutrophils.
Antimicrobial susceptibility testing
Antimicrobial susceptibility test (ASTs) was performed by dilution method (Vitek2 compact) and disk diffusion method. The ASTs breakpoint criteria of Clinical and Laboratory Standards Institute (CLSI) M100 S29 were adopted . The ASTs were applied to penicillin, erythromycin, clindamycin, levofloxacin, sulfamethoxazole-trimethoprim (TMP-SMX), gentamicin, rifampin and minocycline. The dilution method (Vitek2 compact) was applied to penicillin, erythromycin, clindamycin, levofloxacin, sulfamethoxazole-trimethoprim (TMP-SMX), gentamicin, and rifampin, while the disk diffusion method was applied to minocycline.
Staphylococcus aureus ATCC 25,922, ATCC 29,213, ATCC 29,212 were included to ensure reproducibility of the antibiotic susceptibility testing procedure.
Statistical significance was calculated by applying the χ2 test or by Fisher’s exact test in the case of small sample sizes, using the SPSS statistics (Version 20) program. A p-value of < 0.05 was considered as statistical significance.
Among 220 included cases, 138 (62.73%) of the neonates were male. The median patients’ age at admission was 16 days (range: 1 day to 30 days). Among these cases, 67 (30.45%) were invasive MRSA infections, including two deaths (2.99%), while 153 (69.55%) were noninvasive infections.
Invasive and noninvasive infections were compared (Table 1). No significant differences were found in sex. The invasive infections of MRSA occurred at a median age of 8 days from admission, which was significantly younger compared to 19 days in noninvasive cases (p = 0.000). Congenital heart disease and low birth weight infant (< 2500 g)(p = 0.008, p = 0.029, respectively), but not preterm neonates and bronchopulmonary dysplasia, were more commonly found in invasive MRSA infections. Compared with noninvasive MRSA infections, invasive cases stayed in hospitals longer (median: 32.5 days [interquartile range: 1.0–305.0 days] vs. median: 11.0 days [interquartile range: 3.0–153.0 days]; p = 0.000 by the Mann-Whitney U-Test) and had a greater mortality rate (2.99% vs. 0.00%).
The clinical characteristics of patients with invasive MRSA infections are shown in Table 2. Sixty-seven patients (30.45%) had invasive MRSA infections, of which two infants died (2.99%). Septicemia (86.6%) was the most common invasive infection, followed by pneumonia (7.4%), bone and joint infections (3.0%), central nervous system (CNS) infection (1.5%), peritonitis (1.5%), sepsis with pneumonia and bone and joint infections (n = 1). The most commonly used antibiotics were vancomycin or combination with beta-lactam (76.1%), with linezolid being used in 10 cases. The cure rates were 90.2% and 92.9%, respectively.
We analyzed the clinical features of the two departed patients, a boy, and a girl. They were 1 day and 13 days old at admission, respectively. Both patients had underlying diseases of congenital heart disease. Their clinical symptoms included sepsis with pneumonia and sepsis with skin and soft tissue infection (SSTI), respectively. These two patients received vancomycin in combination with a beta-lactam for 20 days and 14 days, respectively. Unfortunately, the two patients experienced no improvement in the severity of the infection and eventually died.
Bacterial identification and antibiotic susceptibility tests
A total of 228 MRSA clinical isolates were obtained. All these isolates were susceptible to vancomycin and linezolid and were resistant to penicillin. Additionally, 69.37% of them were resistant to erythromycin, 57.66% to clindamycin, 7.04% to levofloxacin, 4.62% to sulfamethoxazole-trimethoprim (TMP-SMX), 4.29% to minocycline, 1.33% to gentamicin, and 3.13% were intermediate to rifampin (Fig. 1).
Of the MRSA isolated from invasive infections, 78.38% were resistant to erythromycin, 63.51% were resistant to clindamycin, 10.00% were resistant to levofloxacin, 5.56% were resistant to TMP-SMX, 7.69% to minocycline, and 1.35% were resistant to gentamicin. The erythromycin-resistance rate of the strains isolated from invasive infections was higher than that of the noninvasive infections strains (78.38% vs. 64.86%; p = 0.039; Table 3).
The antibiotic resistance of MRSA strains isolated from different infection sites is summarized in Table 4. The levofloxacin-resistance rates of blood-derived MRSA strains were significantly higher than that of soft tissue-derived strains (15.38% vs. 3.06%, p = 0.009).
MRSA is a particularly threatening pathogen found in neonates. While invasive MRSA infections have been associated with high morbidity and mortality in NICU, the clinical features and risk of invasive MRSA infections in the neonate have not yet been fully described. Accordingly, we conducted this large retrospective study of neonatal MRSA infections with a relatively high rate of invasive diseases across various regions in China.
Sixty-seven neonates (30.45%) in our study developed invasive MRSA infections, and fifty-eight (26.36%) had sepsis. Over recent years, outbreaks of MRSA infection among neonates have been increasingly reported [11, 12]. Although skin and soft tissue infections (SSTIs) are common manifestations of MRSA infections in neonates, invasive diseases, such as bacteremia, necrotizing pneumonia, osteomyelitis, myositis, empyema, meningitis, and septic shock, were also identified and were often accompanied by complications [5, 13]. The first report on invasive MRSA infection, which was from the neonatal ward in the United States in 1981, described a patient who had persistent bacteremia and multiple bone osteomyelitis . Subsequently, numerous invasive MRSA infections were reported in various regions . In a ten-year retrospective study in the UK, including a period between 1993 and 2003, 27% of 30 neonates with S.aureus bacteremia had MRSA bacteremia . In the United States, MRSA has become a significant cause of sepsis in neonates since 2003, accounting for 47% of neonatal bacteremia due to S.aureus . The increasing incidence and more severe outcomes of MRSA bloodstream infections among neonates were observed by Dolapo O (from 24 to 55%) . In 2014, Lim et al. reported a case of MRSA necrotizing pneumonia with empyema in healthy neonates, who finally accepted pneumonectomy . Sepsis is an important cause of mortality in neonates. Previous studies have reported that the case fatality risk for neonatal MRSA sepsis ranges from 9.5 to 55% [6, 17].
Several risk factors associated with severe invasive MRSA infections have been studied. Preterm, premature rupture, low birth weight, and cesarean section delivery have been associated with increased risk of invasive MRSA infection among neonates in multiple studies [18,19,20]. Yet, the birth weight was in response to multiple factors, such as the maternal pre-pregnancy age, smoking, and multiple gestations. Therefore, further studies are needed to address this issue. Several studies reported that the attack rate of neonatal sepsis was significantly increased in infants in the presence of a maternal history of infectious diseases [9, 21]. In contrast to other studies, Denkel et al. reported no risk factors for transmission of MRSA from mother to infant . This study found strong associations between low age at admission (≤ 8 days), congenital heart disease, low birth weight, malnutrition, and invasive MRSA infections. Poorly developed host defense mechanism, prolonged parenteral nutrition, and the use of gastrointestinal tract tube and central venous catheter placement increased the risk of invasive MRSA infection in neonates with low birth weight and malnutrition. Our results are in accordance with studies from the National Institute of Child Health and Human Development Neonatal Research Network .
Antibiotic susceptibility monitoring in NICUs is crucial for clinicians to opt for the most appropriate empirical antimicrobial therapies for neonates suspected of MRSA infection. Over the past 10 years, surveillance studies of MRSA infections in NICUs have reported high resistance rates to erythromycin, clindamycin, and ciprofloxacin, while the majority of MRSA isolates were susceptible to TMP-SMX, tetracycline, rifampin, linezolid, ceftaroline, chlorhexidine, and mupirocin [3, 24, 25]. So far, there are no reports of vancomycin-intermediate S. aureus (VISA) or vancomycin-resistant S. aureus (VRSA) infections in neonates, which were firstly reported in adults in 1996 and 2002 [26, 27]. In the present study, no strains showed to be resistant to vancomycin, linezolid, or rifampin. High resistance rates to erythromycin, clindamycin and occasional resistance rates to levofloxacin, TMP-SMX, and gentamicin were observed.
The use of antibiotic treatment is a particular concern because of the limitation in antibiotic classes among neonates. Intravenous vancomycin is recommended for children with invasive MRSA infections. Nevertheless, vancomycin monotherapy have signifcant limitations such as slow bactericidal activity, poor tissue penetration, uncertain optimal dosing, and vancomycin exposure in invasive MRSA is associated with reduced vancomycin susceptibility. Combination antimicrobial therapies has been advocated as an alternative strategy to improve patient outcomes. Combination therapy with vancomycin plus beta-lactams for MRSA bacteremia showed lower clinical failure rates, and the combination exposures significantly suppresses the development of VISA [28, 29]. Several studies have documented that adding a beta-lactam to vancomycin or daptomycin may help shorten bacteremia and avoid recurrences in patients with MRSA bacteremia . Daptomycin is not routinely used in neonates because of a scarcity of literature on its efficacy and safety in infants. but numerous cases have shown the benefits and relative safety of daptomycin use in neonates [31, 32]. Daptomycin may be considered in cases of clinical failure with vancomycin. The combination of daptomycin plus beta-lactams has been shown to be more effective for the treatment of invasive MRSA infections, such as bacteremia and endocarditis, as they have a synergistic effect between them [33,34,35]. However, a randomized clinical trial from 2015 to 2018 showed that combining a beta-lactam with standard therapy with vancomycin or daptomycin was not associated with reduced treatment failure and mortality . Meta-analysis suggested that the combination therapy could improve some microbial outcomes, but it could not reduce mortality [37, 38]. In our study, septicemia was the most common invasive infection, in which 53.7% were treated with vancomycin plus beta-lactams, and over 90.0% of them were cured. Future studies are warranted to determine the optimal combination regimen for the treatment of invasive MRSA infections. Additionally, a number of novel antimicrobials and adjunctive therapies are in development, including phage therapy, photodynamic treatment, and combinatorial therapeutic used with nanoparticles and Oil Compounds [39,40,41,42,43].
Limitation of the study
Our study has several limitations. As this was a retrospective study, it was not possible to rule out confounding factors and to fully explore the clinical data. Information on the maternal history of bacterial colonization, infectious diseases, and obstetric risk factors are lacking. The major strengths of our data are multicenter nature of the study, and the fact that data of this type for neonatal invasive MRSA infections are relatively lacking. Future studies on invasive MRSA infections in newborns are needed to further verify our findings.
In conclusion, the susceptibility of newborns may contribute to the outbreak of invasive MRSA infections. Invasive infections should be monitored in neonates with high-risk factors, such as low age at admission (≤8 days), congenital heart disease, and low birth weight. As MRSA has low resistance to vancomycin and linezolid, they are recommended in controlling invasive MRSA infections in neonates.
All data generated or analysed during this study are included in this published article and its supplementary information files.
Methicillin-resistant Staphylococcus aureus
Infectious Diseases Surveillance of Pediatrics
Clinical and Laboratory Standards Institute
Neonatal intensive care units
Skin and soft tissue infections
Systemic inflammatory response syndrome
Vancomycin-intermediate S. aureus
Vancomycin-resistant S. aureus.
Weeks JL, Garcia-Prats JA, Baker CJ. Methicillin-resistant Staphylococcus aureus osteomyelitis in a neonate. Jama-Journal of the American Medical Association. 1981;245:1662–4.
Lazenby GB, Soper DE, Beardsley W, Salgado CD. Methicillin-resistant Staphylococcus aureus colonization among women admitted for preterm delivery. Am J Obstet Gynecol. 2012;206:321–9.
Reich PJ, Boyle MG, Hogan PG, Johnson AJ, Wallace MA, Elward AM, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus strains in the neonatal intensive care unit: an infection prevention and patient safety challenge. Clin Microbiol Infect. 2016;22:641–5.
Song X, Perencevich E, Campos J, Short BL, Singh N. Clinical and economic impact of Methicillin-Resistant Staphylococcus aureus colonization or infection on Neonates in Intensive Care Units. Infect Control Hosp Epidemiol. 2010;31:177–82.
Fortunov RM, Hulten KG, Hammerman WA Jr, Mason EO, Kaplan SL. Evaluation and treatment of community-acquired Staphylococcus aureus infections in term and late-preterm previously healthy neonates. Pediatrics. 2007;120:937–45.
Tumuhamye J, Sommerfelt H, Bwanga F, Ndeezi G, Mukunya D, Napyo A, et al. Neonatal sepsis at Mulago national referral hospital in Uganda: etiology, antimicrobial resistance, associated factors and case fatality risk. PLoS ONE. 2020;15:e237085.
Healy CM, Hulten KG, Palazzi DL, Campbell JR, Baker CJ. Emergence of new strains of methicillin-resistant Staphylococcus aureus in a neonatal intensive care unit. Clin Infect Dis. 2004;39:1460–6.
Denniston S, Riordan FAI. Staphylococcus aureus bacteraemia in children and neonates: a 10 year retrospective review. J Infect. 2006;53:387–93.
Shane AL, Sanchez PJ, Stoll BJ. Neonatal sepsis. Lancet. 2017;390:1770–80.
Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing [S]. 29th informational supplement. 2019. M100S 29th ed.
Lee H, Kim ES, Choi C, Seo H, Shin M, Bok JH, et al. Outbreak among healthy newborns due to a new variant of USA300-related meticillin-resistant Staphylococcus aureus. J Hosp Infect. 2014;87:145–51.
Kristinsdottir I, Haraldsson A, Thorkelsson T, Haraldsson G, Kristinsson KG, Larsen J, et al. MRSA outbreak in a tertiary neonatal intensive care unit in Iceland. Infect Diseases-Nor. 2019;51:815–23.
Martini S, Tumietto F, Sciutti R, Greco L, Faldella G, Corvaglia L. Methicillin-resistant Staphylococcus aureus mandibular osteomyelitis in an extremely low birth weight preterm infant. Ital J Pediatr. 2015;41:54.
Takahashi N, Nishida H, Kato H, Imanishi K, Sakata Y, Uchiyama T. Exanthematous disease induced by toxic shock syndrome toxin 1 in the early neonatal period. Lancet. 1998;351:1614–9.
Dolapo O, Dhanireddy R, Talati AJ. Trends of Staphylococcus aureus bloodstream infections in a neonatal intensive care unit from 2000–2009. BMC Pediatr. 2014;14:121.
Lim WH, Lien R, Huang Y, Lee WJ, Lai JY. Community-associated methicillin-resistant Staphylococcus aureus necrotizing pneumonia in a healthy neonate. J Microbiol Immunol Infect. 2014;47:555–7.
Kayange N, Kamugisha E, Mwizamholya DL, Jeremiah S, Mshana SE. Predictors of positive blood culture and deaths among neonates with suspected neonatal sepsis in a tertiary hospital, Mwanza- Tanzania. BMC Pediatr. 2010;10:39.
Schrag SJ, Cutland CL, Zell ER, Kuwanda L, Buchmann EJ, Velaphi SC, et al. Risk factors for neonatal Sepsis and Perinatal Death among Infants enrolled in the Prevention of Perinatal Sepsis Trial, Soweto, South Africa. Pediatr Infect Disease J. 2012;31:821–6.
Murthy S, Godinho MA, Guddattu V, Edward L, Lewis S, Nair NS. Risk factors of neonatal sepsis in India: a systematic review and meta-analysis. PLoS ONE. 2019;14:e215683.
Sakaki H, Nishioka M, Kanda K, Takahashi Y. An investigation of the risk factors for infection with methicillin-resistant Staphylococcus aureus among patients in a neonatal intensive care unit. Am J Infect Control. 2009;37:580–6.
Akalu TY, Gebremichael B, Desta KW, Aynalem YA, Shiferaw WS, Alamneh YM. Predictors of neonatal sepsis in public referral hospitals, Northwest Ethiopia: a case control study. PLoS ONE. 2020;15:e234472.
Denkel LA, Schwab F, Kola A, Leistner R, Garten L, von Weizsaecker K, et al. The mother as most important risk factor for colonization of very low birth weight (VLBW) infants with extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E). J Antimicrob Chemother. 2014;69:2230–7.
Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD neonatal Research Network. Pediatrics. 2002;110:285–91.
Nelson MU, Bizzarro MJ, Baltimore RS, Dembry LM, Gallagher PG. Clinical and molecular epidemiology of Methicillin-Resistant Staphylococcus aureus in a neonatal intensive care unit in the Decade following implementation of an active detection and isolation program. J Clin Microbiol. 2015;53:2492–501.
Murai T, Okazaki K, Kinoshita K, Uehara Y, Zuo H, Lu Y, et al. Comparison of USA300 with non-USA300 methicillin-resistant Staphylococcus aureus in a neonatal intensive care unit. Int J Infect Dis. 2019;79:134–8.
Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 1997;40:135–6.
Chang S, Sievert DM, Hageman JC, Boulton ML, Tenover FC, Downes FP, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med. 2003;348:1342–7.
Zheng X, Berti AD, McCrone S, Roch M, Rosato AE, Rose WE, et al. Combination antibiotic exposure selectively alters the development of Vancomycin Intermediate Resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 2018;62:e02100–17.
Kale-Pradhan PB, Giuliano C, Jongekrijg A, Rybak MJ. Combination of vancomycin or daptomycin and Beta-lactam antibiotics: a Meta-analysis. Pharmacotherapy. 2020;40:648–58.
Garcia Aragones L, Blanch Sancho JJ, Segura Luque JC, Mateos Rodriguez F, Martizez Alfaro E. Solis Garcia Del Pozo J. What do beta-lactams add to vancomycin or daptomycin in the treatment of patients with methicillin-resistant Staphylococcus aureus bacteraemia? A review. Postgrad Med J. 2022;98:48–56.
Chan JI, Noor A, Clauss C, Aggarwal R, Nayak A. Methicillin-Resistant Staphylococcus aureus Endovascular infection in a neonate: prolonged, Safe, and effective use of Daptomycin and Enoxaparin. J Pediatr Pharmacol Ther. 2020;25:68–74.
Gawronski KM. Successful use of Daptomycin in a Preterm Neonate with Persistent Methicillin-Resistant Staphylococcus epidermidis Bacteremia. J Pediatr Pharmacol Ther. 2015;20:61–5.
Duss F, De La Garcia C, Croxatto A, Giulieri S, Lamoth F, Manuel O, et al. Successful treatment with daptomycin and ceftaroline of MDR Staphylococcus aureus native valve endocarditis: a case report. J Antimicrob Chemother. 2019;74:2626–30.
Geriak M, Haddad F, Rizvi K, Rose W, Kullar R, LaPlante K, et al. Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia. Antimicrob Agents Chemother. 2019;63:e02483–18.
Corcione S, Lupia T, Pallotto C, Giacobbe DR, De Benedetto I, Stroffolini G, et al. Beta Lactams Plus Daptomycin Combination Therapy for Infective Endocarditis: an Italian National Survey (BADAS). Antibiot (Basel). 2022;11:56.
Tong SYC, Lye DC, Yahav D, Sud A, Robinson JO, Nelson J, et al. Effect of Vancomycin or Daptomycin with vs without an antistaphylococcal beta-lactam on Mortality, Bacteremia, Relapse, or treatment failure in patients with MRSA Bacteremia A Randomized Clinical Trial. Jama-Journal of the American Medical Association. 2020;323:527–37.
Wang C, Ye C, Liao L, Wang ZH, Hu Y, Deng C, Liu L. Adjuvant beta-lactam therapy combined with vancomycin or daptomycin for Methicillin-Resistant Staphylococcus aureus Bacteremia: a systematic review and Meta-analysis. Antimicrob Agents Chemother. 2020;64:1377–1320.
Yi Y, Wang J, Yin W, Xu WH. Vancomycin or Daptomycin Plus a beta-lactam Versus Vancomycin or Daptomycin alone for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections: a systematic review and Meta-analysis. Microb Drug Resist. 2021;27:1044–56.
Alvarez A, Fernandez L, Gutierrez D, Iglesias B, Rodriguez A, Garcia P. Methicillin-Resistant Staphylococcus aureus in Hospitals: latest Trends and Treatments based on bacteriophages. J Clin Microbiol. 2019;57:e01006–19.
Lehman SM, Mearns G, Rankin D, Cole RA, Smrekar F, Branston SD, et al. Design and Preclinical Development of a phage product for the treatment of antibiotic-resistant Staphylococcus aureus Infections. Viruses-Basel. 2019;11:88.
Drury SL, Miller AR, Laut CL, Walter AB, Bennett MR, Su M, et al. Simultaneous exposure to intracellular and extracellular photosensitizers for the treatment of Staphylococcus aureus Infections. Antimicrob Agents Chemother. 2021;65:e00919–21.
Beha MJ, Ryu JS, Kim YS, Chung HJ. Delivery of antisense oligonucleotides using multi-layer coated gold nanoparticles to methicillin-resistant S. aureus for combinatorial treatment. Volume 126. C-Materials for biological applications: Materials Science & Engineering; 2021. p. 112167.
Kwiatkowski P, Łopusiewicz A, Pruss A, Kostek M, Sienkiewicz M, Bonikowski R, et al. Antibacterial activity of selected essential oil compounds alone and in combination with β-Lactam antibiotics against MRSA strains. Int J Mol Sci. 2020;21:7106.
We would like to thank all investigators of the Group of Infectious Diseases Surveillance of Paediatrics (ISPED) of China who have participated in this study.
This research was funded by the Key Development Program of Children’s Hospital of Fudan University, grant number EK2022ZX05.
Ethics approval and consent to participate
The study protocol was approved by the Ethics Committee of the Children’s Hospital of Fudan University (No. (2020)321). This study was conducted according to the guidelines laid down in the Declaration of Helsinki. The need for Informed Consent was waived by the Ethics Committee of the Children’s Hospital of Fudan University due to the retrospective nature of the study.
Consent for publication
The authors have no conflicts of interest relevant to this article.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Wu, X., Wang, C., He, L. et al. Clinical characteristics and antibiotic resistance profile of invasive MRSA infections in newborn inpatients: a retrospective multicenter study from China. BMC Pediatr 23, 264 (2023). https://doi.org/10.1186/s12887-023-04084-0
- Methicillin-resistant Staphylococcus aureus
- Invasive infection
- Clinical characteristics
- Antimicrobial resistance